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Methylene blue and peritoneal
dialysis
To the Editor: I have read with interest the case presented
by Wu et al.1 regarding urinary bladder perforation
after implantation of a peritoneal dialysis (PD) catheter.
The colored picture showing methylene blue in the efﬂuent
dialysate in the PD bag is quite impressive for the general
practitioner, but nephrologists involved in the ﬁeld of PD may
express several objections regarding this approach.
There are several reports that methylene blue may be an
irritant to the peritoneum and cause chemical peritonitis,
and thus, it is not advisable to use it for diagnostic reasons
in PD.2,3 The unexpected glycosuria and the abdominal
computed tomography imaging should be sufﬁcient to
establish the correct diagnosis, as in other cases.4
The patient of Wu et al.1 was transferred to maintenance
hemodialysis. However, I would not consider the use of
methylene blue in PD for diagnostic reasons as a wise
approach, as the main focus of PD remains to preserve the
peritoneum for as long as possible.
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The Authors Reply: We appreciate Dr Fourtounas1 for his
interest in our work.2 We agree that the unexpected
glycosuria and the abdominal computed tomography imaging
highly suggested that the urinary bladder might be perforated
by the peritoneal dialysis (PD) catheter. However, we think
a conﬁrmatory test is still needed to make the decision
to remove a newly inserted PD catheter. The reason for
Dr Fourtounas’ objection to use methylene blue-stained
dialysate in PD patients is fear of chemical peritonitis. We
fully agree that nephrologists should try to preserve
peritoneum as long as possible. However, we searched the
literature on this issue and found only two case reports that
are also mentioned in the letter.1 In addition, we found seven
PD patients who have been reported to receive intraperitoneal
use of methylene blue-stained dialysate and video-assisted
thoracoscopic surgery to detect and repair their pleuroper-
itoneal communications.3–6 None of them developed chemical
peritonitis and all of them resumed PD well. Therefore,
whether the use of methylene blue-stained dialysate for
diagnostic purposes is contraindicated in PD patients is still a
matter of debate. Furthermore, in this patient, the immediate
presence of blue urine in the urinary bag indicated that most
of the methylene blue-stained dialysate was infused directly
into the urinary bladder, rather than the peritoneal cavity.
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Effects of angiotensin-converting
enzyme inhibitors and angiotensin
II receptor blockers on peritoneal
transport
To the Editor: I have read the excellent revision by Nessim
et al.1 entitled ‘The renin–angiotensin–aldosterone system in
peritoneal dialysis: is what is good for the kidney also good for
the peritoneum?’. In the part of the article where the authors
describe the potential strategies for peritoneal membrane
preservation, they stated that the ﬁrst study in this area with
human data was published in 2007 by Kolesnyk et al. in
Peritoneal Dialysis International.2 However, this is incorrect,
because the ﬁrst study, published in Nephron, about the
effects of angiotensin-converting enzyme inhibitors (ACEIs)
on peritoneal membrane transport was a short-term study
that included 12 diabetic patients on continuous ambulatory
peritoneal dialysis and that showed the decrease of peritoneal
protein losses with the oral administration of captopril, as
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early as in 1989, by Coronel et al.3 This effect was also
demonstrated again by our group in 2004 in patients on
peritoneal dialysis (PD) with an angiotensin receptor blocker
(irbesartan); besides the decrease of peritoneal protein leakage
and proteinuria, irbesartan was also shown to induce changes
in other peritoneal membrane functions.4 Both studies are
mentioned by Kolesnyk et al.5 in their recent review as the
ﬁrst studies in PD patients with this approach.
Studies with ACEIs, angiotensin receptor blockers, or other
substances that can modify peritoneal transport and maybe
improve technique survival still are needed, but we wish to
point out our modest contribution.
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The Authors Reply: We thank Dr Coronel for his
comments.1 Indeed, over two decades ago, Coronel et al.2
examined the effects of blockade of the renin–angiotensin–
aldosterone system (RAAS) on peritoneal membrane function.
Although the two studies mentioned were both small with
a short exposure time to RAAS blocking agents,2,3 they were
the earliest studies to report the effect of blocking the RAAS
on peritoneal membrane function in peritoneal dialysis
patients, setting the stage for the subsequent, larger-scale
observational studies by Kolesnyk et al.4,5 Unfortunately, we
were limited in the number of references for this mini-review,
and did not have the opportunity to discuss these smaller
early studies.
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The missing ‘interstitial vasculitis’
To the Editor: In a recent review on acute interstitial
nephritis (AIN),1 the authors state that AIN may be
associated with systemic disorders such as sarcoidosis,
Sjogren, or systemic lupus erythematosus, but they did not
mention the ‘interstitial vasculitis’, that is, AIN as the only
expression of renal vasculitis.
However, the occurrence of an involvement conﬁned to
the capillaries of renal tubular and interstitial structures in
the setting of systemic vasculitides has been clearly stated in
previous papers published by the European Vasculitis Study
group2 and others.3
Although interstitial vasculitis associated with glomerular
vasculitis is a common observation, interstitial vasculitis as
the only expression of renal involvement in systemic
vasculitides is a rare entity reported in 1% of cases. Pathogenic
mechanisms are presumed to be the same as described in
systemic vasculitis, eventually leading to the destruction of
the capillary walls of peritubular and interstitial capillaries
due to the consequences of inﬂammatory reaction from the
inﬁltrated cells.
However, the most intriguing point is the unknown
reasons for which the occurrence of this kind of vasculitis
only conﬁned to the tubular and interstitial capillary walls is
so rare an event. Some reports of the literature3,4 and our
personal experience in one case might suggest the existence
of a speciﬁc nosographic entity characterized by the co-
existence of giant cell (temporal) arteritis, polymyalgia
rheumatica, and renal interstitial vasculitis. Therefore, we
Table 1 | Etiology of biopsy-proven acute interstitial nephritis
(modified from Praga and Gonza´lez1)
Drugs Antibiotics, NSAIDs, acyclovir, allopurinol,
furosemide, omeprazole, etc.
Infections Bacteria, viruses, others
Associated with
systemic diseases
Sarcoidosis, Sjogren, systemic lupus
erythematosus, vasculitis
Idiopathic Anti-TBM, etc.
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